• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Stevanato Group

Stevanato Group, Owen Mumford to collaborate on Aidaptus auto-injector

May 4, 2022 By Sean Whooley

Owen Mumford aidaptus cms_2 Stevanato Group

Stevanato Group (NYSE:STVN) announced today that it signed an exclusive agreement with Owen Mumford for its auto-injector technology. Piombino Dese, Italy-based Stevanato Group’s agreement makes it an exclusive manufacturing partner for Owen Mumford’s Aidaptus auto-injector. Under the agreement, Stevanato Group will mold the components for the technology and provide final and sub-assembly equipment, along with […]

Filed Under: Auto-injectors, Business/Financial News, Contract Services, Drug-Device Combinations, Featured Tagged With: Owen Mumford, Stevanato Group

Stevanato Group, Bexson expand partnership for wearable drug delivery device

April 29, 2022 By Sean Whooley

Stevanato Group SG EZ be Pod®

Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration. Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Pain Management Tagged With: Bexson Biomedical, Stevanato Group

Stevanato Group acquires facility set to become manufacturing hub in China

March 10, 2022 By Sean Whooley

Stevanato Group

Stevanato Group (NYSE:STVN) announced today that it acquired a facility in Zhangjiagang, China, for a new manufacturing plant. Piombino Dese, Italy-based Stevanato Group expects to begin renovations on the facility in the spring of 2022 as it works to expand in China with a new manufacturing hub for drug containment, drug delivery and diagnostic development. […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Stevanato Group

Stevanato Group extends licensing agreement with Haselmeier for pen injector tech

January 26, 2022 By Sean Whooley

Stevanato Group Alina pen injector

Stevanato Group (NYSE:STVN) announced today that it signed an extension to a licensing agreement with Haselmeier over its pen injector technology. Piombino Dese, Italy-based Stevanato Group’s license extension gives the company exclusivity to offer the Axis-D pen injector technology in support of a broader range of drugs for its biopharma customers beyond diabetes, including areas […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: haselmeier, Stevanato Group

FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump

November 18, 2021 By Sean Whooley

Bexson Biomedical Ketamine Pump

Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy. Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group. According to a news release, having reached the milestone of pre-IND guidance, […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Neurological, Pain Management Tagged With: Bexson Biomedical, FDA, Stevanato Group

Stevanato Group expands corporate headquarters

November 17, 2021 By Sean Whooley

stevanato Group Italy Facility

Stevanato Group (NYSE:STVN) announced today that it expanded its corporate headquarters with a new facility in Italy. Based in Piombino Dese, Italy, Stevanato Group said the 6,750-square-meter facility will support the optimization of its industrial footprint while advancing operations and growth within the company. About 2,500 square meters of the facility will be dedicated to […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Stevanato Group

Stevanato Group beats The Street in Q3, raises guidance

November 9, 2021 By Sean Whooley

Stevanato Group

Stevanato Group (NYSE:STVN) shares hit a snag today despite third-quarter results that beat the consensus forecast. The Piombino Dese, Italy-based drug delivery technology developer posted profits of $21.6 million, or 8¢ per share, on sales of $248.6 million for the three months ended Sept. 30, 2021, for a 12.5% bottom-line gain on sales growth of […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Stevanato Group

Stevanato Group is constructing a new facility in Indiana

October 4, 2021 By Sean Whooley

Stevanato Group

Stevanato Group (NYSE:STVN) announced today that it will begin construction on a new U.S. facility in Fishers, Indiana. Piombino Dese, Italy-based Stevanato Group will begin construction on the new facility this month with expectations for the site to be operational in 2023. According to a news release, constructing the new facility falls in line with […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Stevanato Group

Stevanato Group brings in upsized IPO worth $453.5M

August 17, 2021 By Sean Whooley

Stevanato Group

Stevanato Group announced today that the underwriters of its recently completed initial public offering purchased more than 1 million additional shares. The option exercised by the underwriters saw the acquisition of an additional 1,018,280 ordinary Stevanato Group shares at $21 per share. Piombino Dese, Italy–based Stevanato Group’s IPO resulted in net proceeds of approximately $453.5 […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Pharmaceuticals, Wall Street Beat Tagged With: Bexson Biomedical, infusion pump, initial public offering, IPO, shareholders, Stevanato Group, subcutaneous

Bexson Biomedical wins U.S. patent for ketamine formulation

April 30, 2021 By Sean Whooley

Bexson Biomedical Ketamine Pump

Bexson Biomedical announced that the U.S. Patent and Trademark Office (USPTO) granted a patent for its BB106 ketamine therapy. Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Regulatory/Compliance Tagged With: Bexson Biomedical, Stevanato Group

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS